Premium
Enanta Pharmaceuticals Inc (ENTA)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-02-12 | Mr. Matthew P. KowalskyChief Legal Officer & Corporate Secretary | -1,90k | 27,10k | Sale to Issuer | 14,25 | 3,59k | -34,63% |
| 2026-02-12 | Mr. Brendan LuuChief Business Officer | -3,26k | 46,41k | Sale to Issuer | 14,25 | 37,01k | -8,09% |
| 2026-02-12 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -3,26k | 46,41k | Sale to Issuer | 14,25 | 29,30k | -10,00% |
| 2026-02-12 | Dr. Scott T. RottinghausChief Medical Officer | -3,41k | 48,64k | Sale to Issuer | 14,25 | 18,50k | -15,57% |
| 2026-02-12 | Dr. Yat Sun OrChief Scientific Officer | -3,41k | 48,64k | Sale to Issuer | 14,25 | 369,60k | -0,91% |
| 2026-02-12 | Dr. Jay R. LulyPresident, CEO & Director | -6,16k | 87,71k | Sale to Issuer | 14,25 | 856,12k | -0,71% |
| 2025-12-05 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -323,00 | 4,60k | Vente | 14,23 | 1,43k | -18,44% |
| 2025-12-05 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -542,00 | 7,71k | Vente | 14,23 | 3,15k | -14,68% |
| 2025-12-05 | Dr. Scott T. RottinghausChief Medical Officer | -798,00 | 11,36k | Vente | 14,23 | 15,04k | -5,04% |
| 2025-12-05 | Mr. Brendan LuuChief Business Officer | -1,39k | 19,84k | Vente | 14,23 | 33,70k | -3,97% |
| 2025-12-05 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -2,11k | 29,97k | Vente | 14,23 | 26,00k | -7,49% |
| 2025-12-05 | Dr. Yat Sun OrChief Scientific Officer | -2,39k | 34,01k | Vente | 14,23 | 366,14k | -0,65% |
| 2025-12-05 | Dr. Jay R. LulyPresident, CEO & Director | -4,74k | 67,49k | Vente | 14,23 | 826,53k | -0,57% |
| 2025-12-02 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -207,00 | 2,89k | Vente | 13,96 | 690,00 | -23,08% |
| 2025-12-01 | Ms. Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer | -85,00 | 1,20k | Sale to Issuer | 14,12 | 690,00 | -10,97% |
| 2025-12-02 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -380,00 | 5,30k | Vente | 13,96 | 1,91k | -16,61% |
| 2025-12-01 | Mr. Harry R. TroutVP of Finance & Interim Principal Financial Officer | -105,00 | 1,48k | Sale to Issuer | 14,12 | 1,91k | -5,22% |
| 2025-12-01 | Mr. Brendan LuuChief Business Officer | -498,00 | 7,03k | Sale to Issuer | 14,12 | 30,47k | -1,61% |
| 2025-12-01 | Ms. Tara Lynn KiefferChief Product Strategy Officer | -753,00 | 10,63k | Sale to Issuer | 14,12 | 23,48k | -3,11% |
| 2025-12-01 | Dr. Yat Sun OrChief Scientific Officer | -753,00 | 10,63k | Sale to Issuer | 14,12 | 363,28k | -0,21% |
| 2025-12-01 | Dr. Jay R. LulyPresident, CEO & Director | -1,89k | 26,62k | Sale to Issuer | 14,12 | 831,27k | -0,23% |
| 2025-08-08 | Dr. Scott T. RottinghausChief Medical Officer | -2,22k | 15,50k | Sale to Issuer | 6,99 | 14,09k | -13,60% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
